Home » Stocks » SPHS

Sophiris Bio Inc. (SPHS)

Stock Price: $0.0110 USD -0.0001 (-0.90%)
Updated November 20, 3:38 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 379,192
Revenue (ttm) n/a
Net Income (ttm) 37,000
Shares Out 34.47M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 20
Last Price $0.0110
Previous Close $0.0111
Change ($) -0.0001
Change (%) -0.90%
Day's Open 0.0100
Day's Range 0.0100 - 0.0165
Day's Volume 335,652
52-Week Range 0.0035 - 0.94

More Stats

Market Cap 379,192
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 34.47M
Float 34.42M
EPS (basic) n/a
EPS (diluted) 0.00
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.42M
Short Ratio 8.61
Short % of Float 4.12%
Beta 1.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 16.02
Revenue n/a
Operating Income -10.17M
Net Income 37,000
Free Cash Flow -10.54M
Net Cash 465,000
Net Cash / Share 0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -56.39%
ROE n/a
ROIC 16.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.75*
Low
3.75
Current: $0.0110
High
3.75
Target: 3.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20182017201620152014201320122011
Revenue-----5.00--
Gross Profit-----5.00--
Operating Income-15.14-11.92-10.31-13.49-30.04-9.79-19.21-13.30
Net Income-6.78-8.63-11.16-14.20-30.71-11.15-21.19-14.20
Shares Outstanding30.1230.1123.0016.8816.598.033.052.35
Earnings Per Share-0.23-0.29-0.49-0.84-1.85-1.39-6.94-6.05
Operating Cash Flow-13.46-9.97-10.33-14.36-26.23-13.21-18.84-12.34
Capital Expenditures-----0.01--0.03-0.25
Free Cash Flow-13.46-9.97-10.33-14.36-26.24-13.21-18.86-12.60
Cash & Equivalents12.5425.8429.008.3822.7048.159.7223.41
Total Debt7.016.81-5.345.946.8812.0214.70
Net Cash / Debt5.5319.0429.003.0416.7541.27-2.308.71
Assets13.2026.8830.008.8925.5951.8911.5324.80
Liabilities11.4619.2315.676.9910.9011.6116.6317.80
Book Value1.747.6514.321.9114.6940.28-5.117.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sophiris Bio Inc.
Country United States
Employees 6
CEO Randall E. Woods

Stock Information

Ticker Symbol SPHS
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: SPHS

Description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Company for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.